Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Colorescience Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The busiest examiner for this portfolio is KOSAR, AARON J, who is responsible for the 1 pending action. With only 1 distinct examiner and 1 distinct art unit, the company's current prosecution efforts are centralized.
This organizational structure indicates that the company's current patent prosecution is focused on a single technical niche. Navigating only 1 distinct art unit allows the company to adapt to a specific set of examination standards and procedural norms. KOSAR, AARON J serves as the sole point of contact for the current pending workload, which simplifies the communication channel between the applicant and the USPTO.
The absence of examiner diversity means that the outcome of the pending matter is tied to the individual perspective of a single official. In the Biotechnology & Pharmaceuticals sector, such centralization can be advantageous for maintaining a consistent technical narrative. However, it also means that any specific requirements from the examiner will affect the entire active portfolio. Practitioners must ensure precise alignment with this examiner's interpretations to advance the case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, AARON J | 1 | 71.3% | +29.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18491626 | REDNESS CORRECTING SKIN CARE FORMULATIONS | KOSAR, AARON J | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18491626 | REDNESS CORRECTING SKIN CARE FORMULATIONS | KOSAR, AARON J | 1655 | DP | Non-Final OA | — | Pending | Oct 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialColorescience Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Aaron J Kosar has the most, with 1 of Colorescience Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.